Read the complete weekly issue
Reference Range WeeklyIssue 8
A moonlit nightstand holding a CPAP mask and hose beside a single tablet on a saucer, next to an empty made bed.

A weight-loss pill cut sleep apnea breathing pauses over a year

CPAP, the bedside machine that pushes air through a mask to keep the airway open during sleep, is the standard treatment for sleep apnea, and many people find it hard to stick with. Two trials published in JAMA asked whether a daily pill could change the picture.

The pill is orforglipron, sold as Foundayo, a GLP-1 drug. The ATTAIN-OSA program randomly assigned 712 adults with moderate-to-severe sleep apnea and a BMI of at least 27 to the drug or a placebo for 52 weeks. One trial enrolled 363 people not using CPAP; the other enrolled 349 who were.

Breathing interruptions fell by about 18 an hour on orforglipron and about 5 an hour on placebo, with broadly similar results in both trials. People on the drug lost about 10–11% of their body weight, against 1–2% on placebo, and that weight loss probably does much of the work.

Eli Lilly, which makes the drug, funded both trials, and follow-up lasted one year. People with diabetes or mild sleep apnea were excluded. In the non-CPAP trial, 12.2% stopped the drug because of side effects, mainly nausea, diarrhea and constipation, compared with 3.8% on placebo. Foundayo is approved in the US for weight management, not sleep apnea, and the researchers say it should not replace CPAP.

Get the next issue by email

Our weekly newsletter on what is new in health research, explained for curious readers and linked to the original studies. One email a week.

Sources

Source titles are preserved as published.

Reference Range Weekly is for general information. It does not provide medical advice, diagnosis, or treatment.